Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1298-1304

  Lewis, Russell E ^a,b   Albert, Nathan D ^b   Liao, Guangling ^a   Hou, Jingguo ^a   Prince, Randall A ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DOXYCYCLINE; FUNGAL DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS SPORE; IMMUNE DEFICIENCY; INOCULATION; INVASIVE PULMONARY MUCORMYCOSIS; LUNG PARENCHYMA; MOUSE; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHIZOPUS ORYZAE; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; RHIZOPUS; TREATMENT OUTCOME;

EID: 77149147084     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01222-09     Document Type: Article

References (29)

1. Bakker-Woudenberg, I. A., A. F. Lokerse, M. T. ten Kate, J. W. Mouton, M. C. Woodle, and G. Storm. 1993. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis. 168:164-171.
2. Balloy, V., M. Huerre, J. P. Latge, and M. Chignard. 2005. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73:494-503.
3. Becker, M. J., S. de Marie, M. Fens, W. Hop, H. Verbrugh, and I. Bakker-Woudenberg. 2002. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J. Antimicrob. Chemother. 49:813-820.
4. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
5. Boswell, G. W., D. Buell, and I. Bekersky. 1998. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38:583-592.
6. Chamilos, G., R. E. Lewis, and D. P. Kontoyiannis. 2008. Delaying amphotericin B-based front-line therapy significantly increases mortality in hematologic malignancy patients with zygomycosis. Clin. Infect. Dis. 47:503-509.
7. Cornely, O. A., J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H. A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, and R. Herbrecht. 2007. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. 44:1289-1297.
8. Espinel-Ingroff, A., V. Chaturvedi, A. Fothergill, and M. G. Rinaldi. 2002. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 40:3776-3781.
9. Groll, A. H., C. A. Lyman, V. Petraitis, R. Petraitiene, D. Armstrong, D. Mickiene, R. M. Alfaro, R. L. Schaufele, T. Sein, J. Bacher, and T. J. Walsh. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50:3418-3423.
10. Ibrahim, A. S., J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards, Jr., and C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727.
11. Ibrahim, A. S., T. Gebremariam, M. I. Husseiny, D. A. Stevens, Y. Fu, J. E. Edwards, Jr., and B. Spellberg. 2008. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob. Agents Chemother. 52:1573-1576.
12. Kontoyiannis, D. P., and R. E. Lewis. 2006. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect. Dis. Clin. North Am. 20:581-607, vi.
13. Kontoyiannis, D. P., M. S. Lionakis, R. E. Lewis, G. Chamilos, M. Healy, C. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. J. Walsh, and I. I. Raad. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillusactive antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191:1350-1360.
14. Lamaris, G. A., R. Ben-Ami, R. E. Lewis, G. Chamilos, G. Samonis, and D. P. Kontoyiannis. 2009. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J. Infect. Dis. 199:1399-1406.
15. Lass-Florl, C., G. Resch, D. Nachbaur, A. Mayr, G. Gastl, J. Auberger, R. Bialek, and M. C. Freund. 2007. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin. Infect. Dis. 45:e101-e104.
16. Lewis, R. E., N. D. Albert, G. Liao, J. Hou, R. A. Prince, and D. P. Kontoyiannis. 2008. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-2139.
17. Lewis, R. E., G. Liao, J. Hou, G. Chamilos, R. A. Prince, and D. P. Kontoyiannis. 2007. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 51:1253-1258.
18. Lewis, R. E., and N. P. Wiederhold. 2005. Murine model of invasive aspergillosis. Methods Mol. Med. 118:129-142.
19. Linden, P. K. 2003. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin. Pharmacother. 4:2099-2110.
20. Matot, I., and R. Pizov. 2000. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit. Care Med. 28:2528-2532.
21. Mouton, J. W., U. Theuretzbacher, W. A. Craig, P. M. Tulkens, H. Derendorf, and O. Cars. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
22. Neofytos, D., D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, J. Fishman, M. Pfaller, C. Chang, K. Webster, and K. Marr. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
23. Park, B. J., P. Pappas, K. Marr, E. J. Anaissie, J. Ito, B. D. Alexander, T. J. Walsh, and D. P. Kontoyiannis. 2007. Recent epidemiology and zygomycosis among organ transplant and stem cell transplant recipients: results from the TRANSNET surveillance network, abstr. M-618, p. 434. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
25. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
26. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
27. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
28. Wiederhold, N. P., V. H. Tam, J. Chi, R. A. Prince, D. P. Kontoyiannis, and R. E. Lewis. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.
29. Wong-Beringer, A., R. A. Jacobs, and B. J. Guglielmo. 1998. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:603-618.